Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan
© 2024. The Author(s)..
BACKGROUND: Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens. Ceftolozane/tazobactam demonstrated efficacy comparable to meropenem in patients with ventilated hospital-acquired bacterial pneumonia in the ASPECT-NP study. One cost-effectiveness analysis in the United States revealed that ceftolozane/tazobactam was cost effective, but no Japanese studies have been conducted. Therefore, the objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam compared to meropenem for patients with ventilated hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia from a health care payer perspective.
METHODS: A hybrid decision-tree Markov decision-analytic model with a 5-year time horizon were developed to estimate costs and quality-adjusted life-years and to calculate the incremental cost-effectiveness ratio associated with ceftolozane/tazobactam and meropenem in the treatment of patients with ventilated hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Clinical outcomes were based on the ASPECT-NP study, costs were based on the national fee schedule of 2022, and utilities were based on published data. One-way sensitivity analysis and probabilistic sensitivity analysis were also conducted to assess the robustness of our modeled estimates.
RESULTS: According to our base-case analysis, compared with meropenem, ceftolozane/tazobactam increased the total costs by 424,731.22 yen (£2,626.96) and increased the quality-adjusted life-years by 0.17, resulting in an incremental cost-effectiveness ratio of 2,548,738 yen (£15,763.94) per quality-adjusted life-year gained for ceftolozane/tazobactam compared with meropenem. One-way sensitivity analysis showed that although the incremental cost-effectiveness ratio remained below 5,000,000 yen (£30,925) for most of the parameters, the incremental net monetary benefit may have been less than 0 depending on the treatment efficacy outcome, especially the cure rate and mortality rate for MEPM and mortality rate for CTZ/TAZ. 53.4% of the PSA simulations demonstrated that CTZ/TAZ was more cost-effective than MEPM was.
CONCLUSION: Although incremental cost-effectiveness ratio was below ¥5,000,000 in base-case analysis, whether ceftolozane/tazobactam is a cost-effective alternative to meropenem for ventilated hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia in Japan remains uncertain. Future research should examine the unobserved heterogeneity across patient subgroups and decision-making settings, to characterise decision uncertainty and its consequences so as to assess whether additional research is required.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
BMC health services research - 24(2024), 1 vom: 28. März, Seite 389 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Takaya, Risako [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12913-024-10883-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370386868 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370386868 | ||
003 | DE-627 | ||
005 | 20240401233000.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240330s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12913-024-10883-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1359.xml |
035 | |a (DE-627)NLM370386868 | ||
035 | |a (NLM)38549158 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Takaya, Risako |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.04.2024 | ||
500 | |a Date Revised 01.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a BACKGROUND: Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens. Ceftolozane/tazobactam demonstrated efficacy comparable to meropenem in patients with ventilated hospital-acquired bacterial pneumonia in the ASPECT-NP study. One cost-effectiveness analysis in the United States revealed that ceftolozane/tazobactam was cost effective, but no Japanese studies have been conducted. Therefore, the objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam compared to meropenem for patients with ventilated hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia from a health care payer perspective | ||
520 | |a METHODS: A hybrid decision-tree Markov decision-analytic model with a 5-year time horizon were developed to estimate costs and quality-adjusted life-years and to calculate the incremental cost-effectiveness ratio associated with ceftolozane/tazobactam and meropenem in the treatment of patients with ventilated hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Clinical outcomes were based on the ASPECT-NP study, costs were based on the national fee schedule of 2022, and utilities were based on published data. One-way sensitivity analysis and probabilistic sensitivity analysis were also conducted to assess the robustness of our modeled estimates | ||
520 | |a RESULTS: According to our base-case analysis, compared with meropenem, ceftolozane/tazobactam increased the total costs by 424,731.22 yen (£2,626.96) and increased the quality-adjusted life-years by 0.17, resulting in an incremental cost-effectiveness ratio of 2,548,738 yen (£15,763.94) per quality-adjusted life-year gained for ceftolozane/tazobactam compared with meropenem. One-way sensitivity analysis showed that although the incremental cost-effectiveness ratio remained below 5,000,000 yen (£30,925) for most of the parameters, the incremental net monetary benefit may have been less than 0 depending on the treatment efficacy outcome, especially the cure rate and mortality rate for MEPM and mortality rate for CTZ/TAZ. 53.4% of the PSA simulations demonstrated that CTZ/TAZ was more cost-effective than MEPM was | ||
520 | |a CONCLUSION: Although incremental cost-effectiveness ratio was below ¥5,000,000 in base-case analysis, whether ceftolozane/tazobactam is a cost-effective alternative to meropenem for ventilated hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia in Japan remains uncertain. Future research should examine the unobserved heterogeneity across patient subgroups and decision-making settings, to characterise decision uncertainty and its consequences so as to assess whether additional research is required | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Ceftolozane/tazobactam | |
650 | 4 | |a Cost-effectiveness analysis | |
650 | 4 | |a Meropenem | |
650 | 4 | |a Ventilated-hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia | |
650 | 7 | |a ceftolozane |2 NLM | |
650 | 7 | |a 37A4IES95Q |2 NLM | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
650 | 7 | |a Meropenem |2 NLM | |
650 | 7 | |a FV9J3JU8B1 |2 NLM | |
650 | 7 | |a ceftolozane, tazobactam drug combination |2 NLM | |
650 | 7 | |a Tazobactam |2 NLM | |
650 | 7 | |a SE10G96M8W |2 NLM | |
650 | 7 | |a Cephalosporins |2 NLM | |
700 | 1 | |a Mori, Nobuyoshi |e verfasserin |4 aut | |
700 | 1 | |a Saito, Eiko |e verfasserin |4 aut | |
700 | 1 | |a Ohde, Sachiko |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC health services research |d 2001 |g 24(2024), 1 vom: 28. März, Seite 389 |w (DE-627)NLM111682703 |x 1472-6963 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:28 |g month:03 |g pages:389 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12913-024-10883-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2024 |e 1 |b 28 |c 03 |h 389 |